Eszopiclone
- Generic Name
- Eszopiclone
- Brand Names
- Lunesta
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17ClN6O3
- CAS Number
- 138729-47-2
- Unique Ingredient Identifier
- UZX80K71OE
- Background
Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as cyclopyrrolones. Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a safer alternative to other drugs used for insomnia.
One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia. This sets it apart from many other hypnotic sedatives, which are generally approved only for the relief of short-term (6-8 weeks) insomnia. Eszopiclone was initially approved by the FDA in 2004.
- Indication
Eszopiclone is indicated for the treatment of insomnia.
- Associated Conditions
- Insomnia
6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 830
- Registration Number
- NCT00352144
Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2013-05-31
- Target Recruit Count
- 30
- Registration Number
- NCT00324896
- Locations
- 🇺🇸
The New Jersey Neuroscience Institute, Edison,, New Jersey, United States
🇺🇸University of Pennsylvania Medical School, Philadelphia, Pennsylvania, United States
🇺🇸Fusion Sleep Center, Suwanee, Georgia, United States
Improving Sleep and Psychological Functioning in People With Depression and Insomnia
- Conditions
- Sleep Initiation and Maintenance DisordersDepression
- Interventions
- First Posted Date
- 2005-11-02
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT00247624
- Locations
- 🇺🇸
Wake Forest University Health Sciences; Department of Psychiatry and Behavioral Medicine, Winston-Salem, North Carolina, United States
Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
- Conditions
- InsomniaGeneralized Anxiety Disorder
- Interventions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 420
- Registration Number
- NCT00235508
Testing the Nocturnal Sleep Latency Profile in Primary Insomnia
- Conditions
- Primary InsomniaSleep Initiation and Maintenance Disorders
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2008-02-15
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 24
- Registration Number
- NCT00167375
- Locations
- 🇺🇸
Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States
Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder
- First Posted Date
- 2005-07-15
- Last Posted Date
- 2016-04-26
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT00120250
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.